{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:33:31Z","timestamp":1785321211583,"version":"3.55.0"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:p>We present 2 women with advanced invasive ductal carcinoma who developed skeletal metastases despite extensive treatment, including surgery, chemotherapy, and hormonal therapy. Both patients experienced debilitating pain and were evaluated for bone palliation therapy using <jats:sup>177<\/jats:sup>Lu-FAPI-2286, after <jats:sup>99m<\/jats:sup>Tc-FAPI-46 scintigraphy showed suitable uptake. Remarkably, both patients reported significant pain relief shortly after treatment. The only adverse effect noted was grade III thrombocytopenia in 1 patient. These cases highlight the potential of <jats:sup>177<\/jats:sup>Lu-FAPI-2286 in providing rapid and effective palliation for breast cancer patients suffering from refractory pain, suggesting further investigation into its role in theranostics and palliative care. In this report, we also conducted a comprehensive literature review on radio-ligand therapy with <jats:sup>177<\/jats:sup>Lu-FAPI in breast cancer.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005753","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T01:00:10Z","timestamp":1747789210000},"page":"e564-e567","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":8,"title":["Favorable Palliative Effect of 177Lu-FAPI-2286 in Two Breast Cancer Patients With Refractory Bone Pains"],"prefix":"10.1097","volume":"50","author":[{"given":"Nasrin","family":"Raeisi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Saber Tanha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farid","family":"Jafari Zarrin Ghabaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somaye","family":"Barashki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2403-8903","authenticated-orcid":false,"given":"Kamran","family":"Aryana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"R1-20250731","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1007\/s00259-023-06482-z","article-title":"Therapeutic potential of [177Lu]Lu-DOTAGA-FAPi dimers in metastatic breast cancer patients with limited treatment options: efficacy and safety assessment","volume":"51","author":"Yadav","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R2-20250731","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using 177 Lu-FAP-2286: first-in-humans results","volume":"63","author":"Baum","year":"2022","journal-title":"J Nucl Med"},{"key":"R3-20250731","doi-asserted-by":"crossref","first-page":"1358070","DOI":"10.3389\/fonc.2024.1358070","article-title":"Applications of FAPI PET\/CT in the diagnosis and treatment of breast and the most common gynecologic malignancies: a literature review","volume":"14","author":"Li","year":"2024","journal-title":"Front Oncol"},{"key":"R4-20250731","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.3390\/ijms24043863","article-title":"Fibroblast activation protein inhibitor (FAPI)-based theranostics\u2014where we are at and where we are heading: a systematic review","volume":"24","author":"Sidrak","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R5-20250731","first-page":"817","article-title":"The role of theragnostics in breast cancer: a systematic review of the last 12 years","volume":"19","author":"Balma","year":"2023","journal-title":"Curr Med Imaging"},{"key":"R6-20250731","doi-asserted-by":"crossref","first-page":"908","DOI":"10.3390\/cancers15030908","article-title":"PET\/CT with fibroblast activation protein inhibitors in breast cancer: diagnostic and theranostic application\u2014a literature review","volume":"15","author":"Taralli","year":"2023","journal-title":"Cancers (Basel)"},{"key":"R7-20250731","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1007\/s00259-020-04990-w","article-title":"A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET\/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy","volume":"48","author":"Ballal","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R8-20250731","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.36922\/arnm.1667","article-title":"Fibroblast activation protein-targeted radioligand therapy in various types of cancer: background, clinical studies, and future development","volume":"0","author":"Pang","year":"2023","journal-title":"Adv Radiother Nucl Med"},{"key":"R9-20250731","doi-asserted-by":"crossref","first-page":"e410","DOI":"10.1097\/RLU.0000000000003678","article-title":"Theranostic approach in breast cancer","volume":"46","author":"Jokar","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R10-20250731","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.3390\/ph14121212","article-title":"First-In-human results on the biodistribution, pharmacokinetics, and dosimetry of [177Lu]Lu-DOTA.SA.FAPi and [177Lu]Lu-DOTAGA.(SA.FAPi)2","volume":"14","author":"Ballal","year":"2021","journal-title":"Pharmaceuticals"},{"key":"R11-20250731","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cpet.2023.02.007","article-title":"Fibroblast activation protein inhibitor theranostics","volume":"18","author":"Mori","year":"2023","journal-title":"PET Clin"},{"key":"R12-20250731","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1097\/RLU.0000000000003810","article-title":"Feasibility and therapeutic potential of 177Lu\u2013fibroblast activation protein inhibitor\u201346 for patients with relapsed or refractory cancers","volume":"46","author":"Assadi","year":"2021","journal-title":"Clin Nucl Med"},{"key":"R13-20250731","doi-asserted-by":"crossref","first-page":"1236565","DOI":"10.3389\/fnume.2023.1236565","article-title":"Theranostics in breast cancer","volume":"3","author":"Vorster","year":"2023","journal-title":"Front Nucl Med"},{"key":"R14-20250731","first-page":"65","article-title":"Novel fibroblast activation protein inhibitor-based targeted theranostics for radioiodine-refractory differentiated thyroid cancer patients: a pilot study","volume":"32","author":"Ballal","year":"2021","journal-title":"Thyroid"},{"key":"R15-20250731","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cpet.2023.02.008","article-title":"Fibroblast activation protein inhibitor theranostics","volume":"18","author":"Hamacher","year":"2023","journal-title":"PET Clin"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005753","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T05:00:41Z","timestamp":1753938041000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005753","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"2024-11-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-03","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}